135 related articles for article (PubMed ID: 2456010)
1. Urinary pseudouridine as a biochemical marker in the diagnosis and monitoring of primary hepatocellular carcinoma.
Tamura S; Fujioka H; Nakano T; Amuro Y; Hada T; Nakao N; Higashino K
Am J Gastroenterol; 1988 Aug; 83(8):841-5. PubMed ID: 2456010
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of urinary and serum pseudouridine in diagnosis and monitoring of primary liver cancer.
Tu Z; Xu S; Wu M
Chin Med J (Engl); 1995 Mar; 108(3):204-8. PubMed ID: 7796629
[TBL] [Abstract][Full Text] [Related]
3. Urinary excretion of pseudouridine in patients with hepatocellular carcinoma.
Tamura S; Amuro Y; Nakano T; Fujii J; Moriwaki Y; Yamamoto T; Hada T; Higashino K
Cancer; 1986 Apr; 57(8):1571-5. PubMed ID: 2418945
[TBL] [Abstract][Full Text] [Related]
4. Serum pseudouridine as a biochemical marker in small cell lung cancer.
Tamura S; Fujioka H; Nakano T; Hada T; Higashino K
Cancer Res; 1987 Nov; 47(22):6138-41. PubMed ID: 2822241
[TBL] [Abstract][Full Text] [Related]
5. Serum pseudouridine as a biochemical marker in patients with hepatocellular carcinoma.
Amuro Y; Nakaoka H; Shimomura S; Fujikura M; Yamamoto T; Tamura S; Hada T; Higashino K
Clin Chim Acta; 1988 Dec; 178(2):151-8. PubMed ID: 2854011
[TBL] [Abstract][Full Text] [Related]
6. Serum alpha-L-fucosidase activity and tumor size in hepatocellular carcinoma.
Takahashi H; Saibara T; Iwamura S; Tomita A; Maeda T; Onishi S; Yamamoto Y; Enzan H
Hepatology; 1994 Jun; 19(6):1414-7. PubMed ID: 7514563
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
8. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
[TBL] [Abstract][Full Text] [Related]
9. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
[TBL] [Abstract][Full Text] [Related]
10. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study.
Ikoma J; Kaito M; Ishihara T; Nakagawa N; Kamei A; Fujita N; Iwasa M; Tamaki S; Watanabe S; Adachi Y
Hepatogastroenterology; 2002; 49(43):235-8. PubMed ID: 11941963
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with survival exceeding 5 years after transcatheter arterial embolization for hepatocellular carcinoma.
Yoshioka H; Sato M; Sonomura T; Terada M; Kishi K; Yoshikawa A
Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-29-S6-37. PubMed ID: 9151914
[TBL] [Abstract][Full Text] [Related]
12. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
13. A contribution to early diagnosis of primary hepatic cell carcinoma occurring in patients with liver cirrhosis.
Iwamura K
Tokai J Exp Clin Med; 1982 May; 7(3):397-411. PubMed ID: 6181578
[TBL] [Abstract][Full Text] [Related]
14. [Decarboxyprothrombin: importance in the diagnosis of hepatocellular carcinoma].
Bon C; Brillard B; Gelineau MC; Mailliavin A; Trépo C; Pichot J
Ann Biol Clin (Paris); 1998; 56(2):175-81. PubMed ID: 9754243
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey.
Ozer B; Serin E; Yilmaz U; Gümürdülü Y; Saygili OB; Kayaselçuk F; Boyacioğlu S
Turk J Gastroenterol; 2003 Jun; 14(2):85-90. PubMed ID: 14614632
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].
Arima K; Kodama T; Suga M; Sakamoto H; Ohe Y; Yachi A
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968
[TBL] [Abstract][Full Text] [Related]
18. The des-gamma-carboxyprothrombin for the diagnosis of hepatocellular carcinoma.
Brunello F; Marcarino C; Pasquero P; Gastaldi P; Gonella S; Martini S; Calcamuggi G; Emanuelli G
Ital J Gastroenterol; 1993 Jan; 25(1):9-12. PubMed ID: 7679014
[TBL] [Abstract][Full Text] [Related]
19. Intrahepatic arteriovenous shunting due to hepatocellular carcinoma and cirrhosis, and its change by transcatheter arterial embolization.
Sugano S; Miyoshi K; Suzuki T; Kawafune T; Kubota M
Am J Gastroenterol; 1994 Feb; 89(2):184-8. PubMed ID: 8304300
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
